Lv71
3800 积分 2021-05-31 加入
Long-term safety and efficacy of twice-yearly depemokimab in type 2 asthma with an eosinophilic phenotype: 2-year integrated analysis of the phase 3a SWIFT-1 and SWIFT-2 studies and AGILE open-label extension
4天前
已完结
Long-term safety and efficacy of twice-yearly depemokimab in type 2 asthma with an eosinophilic phenotype: 2-year integrated analysis of the phase 3a SWIFT-1 and SWIFT-2 studies and AGILE open-label extension
4天前
已完结
Benralizumab in severe eosinophilic asthma in real life: confirmed effectiveness and contrasted effect on sputum eosinophiliaversusexhaled nitric oxide fraction – PROMISE
21天前
已完结
Benralizumab Normalizes Sputum Eosinophilia in Severe Asthma Uncontrolled by Anti–IL-5 Antibodies: A Single-Blind, Placebo-controlled Clinical Trial
21天前
已完结
Biologic Therapies for Severe Asthma
25天前
已完结
Generation and preclinical assessment of depemokimab, an enhanced IL-5 antagonist monoclonal antibody
1个月前
已完结
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
1个月前
已完结
Biologic Therapies for Severe Asthma
3个月前
已完结
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
3个月前
已完结
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
3个月前
已完结